Highlights
– GLP-1 receptor agonist (GLP-1RA) therapy was associated with an 18% lower risk of atrial fibrillation (AF) recurrence after catheter ablation in patients with obesity.
– Patients on GLP-1RAs showed a 23% reduction in progression to permanent AF and a 27% reduction in all-cause mortality.
– Significant improvements were noted in secondary cardiovascular outcomes, including a 20% reduction in heart failure hospitalizations and a 15% reduction in cardiovascular-related hospitalizations.
